Clinical comparisons of botulinum neurotoxin formulations

Research output: Contribution to journalReview article

26 Citations (Scopus)

Abstract

Background: The expanding uses of botulinum neurotoxin (BoNT) for a growing number of clinical indications, including cervical and other dystonias, adult and childhood spasticity, and hyperhidrosis, in conjunction with the emergence of new formulations of BoNT, prompt discussion of the differences in formulations, serotypes, and indications for different neurologic diseases. Review Summary: This review will evaluate evidence from preclinical studies, prospective treatment studies, and direct comparative trials to discuss the differences among BoNTs and the clinical implications of using these different drugs. Data from these sources indicate that formulations of BoNT are distinct; even the same serotype formulations of BoNT serotype A have different molecular structures and sizes and therapeutic indices (reflected in different safety and efficacy profiles). Conclusion: Taken together, these findings confirm that the different BoNT serotypes, including the different BoNTA formulations, are distinct therapeutic entities.

Original languageEnglish (US)
Pages (from-to)289-298
Number of pages10
JournalNeurologist
Volume14
Issue number5
DOIs
StatePublished - Sep 1 2008
Externally publishedYes

Fingerprint

Neurotoxins
Hyperhidrosis
Torticollis
Information Storage and Retrieval
Nervous System Diseases
Molecular Structure
Prospective Studies
Safety
Serogroup
Therapeutics
Pharmaceutical Preparations

Keywords

  • Bioequivalence
  • Blepharospasm
  • Botulinum toxin
  • Cervical dystonia
  • Dose ratio
  • Hemifacal spasm
  • Spasticity, hyperhidrosis

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Clinical comparisons of botulinum neurotoxin formulations. / Brashear, Allison.

In: Neurologist, Vol. 14, No. 5, 01.09.2008, p. 289-298.

Research output: Contribution to journalReview article

@article{6ed2aa20d53749a086dacf2646b4882a,
title = "Clinical comparisons of botulinum neurotoxin formulations",
abstract = "Background: The expanding uses of botulinum neurotoxin (BoNT) for a growing number of clinical indications, including cervical and other dystonias, adult and childhood spasticity, and hyperhidrosis, in conjunction with the emergence of new formulations of BoNT, prompt discussion of the differences in formulations, serotypes, and indications for different neurologic diseases. Review Summary: This review will evaluate evidence from preclinical studies, prospective treatment studies, and direct comparative trials to discuss the differences among BoNTs and the clinical implications of using these different drugs. Data from these sources indicate that formulations of BoNT are distinct; even the same serotype formulations of BoNT serotype A have different molecular structures and sizes and therapeutic indices (reflected in different safety and efficacy profiles). Conclusion: Taken together, these findings confirm that the different BoNT serotypes, including the different BoNTA formulations, are distinct therapeutic entities.",
keywords = "Bioequivalence, Blepharospasm, Botulinum toxin, Cervical dystonia, Dose ratio, Hemifacal spasm, Spasticity, hyperhidrosis",
author = "Allison Brashear",
year = "2008",
month = "9",
day = "1",
doi = "10.1097/NRL.0b013e31816f2cdd",
language = "English (US)",
volume = "14",
pages = "289--298",
journal = "The neurologist",
issn = "1074-7931",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Clinical comparisons of botulinum neurotoxin formulations

AU - Brashear, Allison

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Background: The expanding uses of botulinum neurotoxin (BoNT) for a growing number of clinical indications, including cervical and other dystonias, adult and childhood spasticity, and hyperhidrosis, in conjunction with the emergence of new formulations of BoNT, prompt discussion of the differences in formulations, serotypes, and indications for different neurologic diseases. Review Summary: This review will evaluate evidence from preclinical studies, prospective treatment studies, and direct comparative trials to discuss the differences among BoNTs and the clinical implications of using these different drugs. Data from these sources indicate that formulations of BoNT are distinct; even the same serotype formulations of BoNT serotype A have different molecular structures and sizes and therapeutic indices (reflected in different safety and efficacy profiles). Conclusion: Taken together, these findings confirm that the different BoNT serotypes, including the different BoNTA formulations, are distinct therapeutic entities.

AB - Background: The expanding uses of botulinum neurotoxin (BoNT) for a growing number of clinical indications, including cervical and other dystonias, adult and childhood spasticity, and hyperhidrosis, in conjunction with the emergence of new formulations of BoNT, prompt discussion of the differences in formulations, serotypes, and indications for different neurologic diseases. Review Summary: This review will evaluate evidence from preclinical studies, prospective treatment studies, and direct comparative trials to discuss the differences among BoNTs and the clinical implications of using these different drugs. Data from these sources indicate that formulations of BoNT are distinct; even the same serotype formulations of BoNT serotype A have different molecular structures and sizes and therapeutic indices (reflected in different safety and efficacy profiles). Conclusion: Taken together, these findings confirm that the different BoNT serotypes, including the different BoNTA formulations, are distinct therapeutic entities.

KW - Bioequivalence

KW - Blepharospasm

KW - Botulinum toxin

KW - Cervical dystonia

KW - Dose ratio

KW - Hemifacal spasm

KW - Spasticity, hyperhidrosis

UR - http://www.scopus.com/inward/record.url?scp=53549097062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53549097062&partnerID=8YFLogxK

U2 - 10.1097/NRL.0b013e31816f2cdd

DO - 10.1097/NRL.0b013e31816f2cdd

M3 - Review article

C2 - 18784598

AN - SCOPUS:53549097062

VL - 14

SP - 289

EP - 298

JO - The neurologist

JF - The neurologist

SN - 1074-7931

IS - 5

ER -